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olcott-Rallison syndrome (OMIM 226980) is a rare
autosomal recessive disorder characterised by per-
manent insulin requiring diabetes developing in the
newborn period or early infancy, an early tendency to skeletal
fractures, and spondyloepiphyseal dysplasia.1–8 The syndrome
results from mutations in the gene encoding the eukaryotic
translation initiation factor 2-a kinase 3 (EIF2AK3, also called
PERK or PEK).9 This enzyme phosphorylates EIF2A at Ser51
to regulate the synthesis of unfolded proteins in the
endoplasmic reticulum.10 Targeted disruption of the Eif2ak3
gene in mice also causes diabetes because of the accumula-
tion of unfolded proteins triggering b cell apoptosis.11 12
Although these murine models have provided significant
insight into the pathogenesis of Wolcott-Rallison syndrome,
only three human cases have been characterised geneti-
cally.8 9 Here, we report genetic analysis of two further cases,
and demonstrate new features of the expression pattern of
human EIF2AK3 that offer possible explanations for impor-
tant clinical features of the syndrome that are not apparent in
the transgenic mouse models.
METHODS
Primers were designed to amplify all EIF2AK3 exons and
splice site sequences from genomic DNA (table 1). Sequences
were amplified by 35 cycles of polymerase chain reaction
(PCR) using a proof-reading DNA polymerase in 50 ml
reactions and purified (Qiaquick, Qiagen, Crawley, Sussex,
UK). Products were sequenced using the BigDye terminator
cycle sequencing kit according to the manufacturer’s instruc-
tions (Perkin-Elmer, Foster City, California, USA) and an ABI
377 sequencer (Applied Biosystems, city, county, UK).
Sequences were compared to the published EIF2AK3 gene
by BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/).
For potential mutations, the PCR and sequencing was
repeated to confirm the result. Restriction digest analysis
was also used to confirm the mutation in case 2, where the
GRA substitution destroyed an HphI site.
Optimal conditions were determined for the anti-human
EIF2AK3 antibody (Santa Cruz Biotechnology, Santa Cruz,
California, USA) by testing the use of several blocking and
antigen unmasking techniques. Previously, specimens used
in this study, which were obtained with permission of our
local ethics committee, have shown positive immunoreactiv-
ity to a range of antibodies, indicating satisfactory tissue
preparation.
Slides were dewaxed, rehydrated, and washed in phos-
phate buffered saline (PBS). Sections were pretreated with
3% (vol/vol) hydrogen peroxide in PBS to quench endogen-
ous peroxidase before antigen retrieval by boiling in 0.3 M
sodium citrate for 10 minutes and incubation with primary
antibody (1:50 dilution) overnight at 4 C˚. Sections were
washed in PBS and incubated with biotinylated anti-goat
secondary antibody for two hours at 4 C˚ (1:300; Vector
Laboratories, Burlingame, California, USA). Further washing
was followed by incubation for one hour at room temperature
with streptavidin conjugated horseradish peroxidase (1:200;
Vector Laboratories) and the colour reaction developed over
three minutes with diaminobenzidine (10 mg/ml) containing
0.1% hydrogen peroxide. Dual immunohistochemistry was
done sequentially with antibodies to islet hormones (all
1:100; Zymed Laboratories, San Francisco, California, USA)
using alkaline phosphatase labelled secondary antibodies
(1:500) and the Vector red staining kit according to the
manufacturer’s instructions (Vector Laboratories). Sections
were counterstained with toluidine blue and viewed with a
Zeiss Axioplan2 imaging system.
RESULTS AND DISCUSSION
Case reports and mutational analyses
Case 1
The clinical history has been detailed previously, and
causative mutation of the PAX4 gene (required for b cell
development) was excluded.6 This individual, born prema-
turely at 28 weeks’ gestation, was the offspring of con-
sanguineous Saudi parents. The diagnosis of diabetes was
made on the fourth day of postnatal life, although insulin
was withdrawn on day 28 until the child re-presented with
Key points
N Wolcott-Rallison syndrome, a rare cause of permanent
neonatal diabetes and spondyloepiphyseal dysplasia,
results from mutations in the gene encoding EIF2AK3.
N We have identified two novel mutations in the EIF2AK3
gene from unrelated cases of this syndrome, including
the first example of splice site mutation as the
pathogenic mechanism.
N Additional phenotypic features included a predilection
to severe unexplained hypoglycaemic episodes sug-
gestive of hepatic impairment, and to renal failure.
These features are not seen in Eif2ak3 knockout mice.
N Immunohistochemical analysis of human adult and
fetal tissues showed that EIF2AK3 was widely
expressed in the epithelial cells of the early fetal
pancreas, and was present in adult b cells and exocrine
tissue. It was also expressed in developing bone,
kidney, and adult liver, consistent with the extended
phenotype of Wolcott-Rallison syndrome.
N These results both broaden the previous molecular
genetic description of this syndrome and provide new
information relevant to the pathogenesis of those
clinical features in affected patients that are not
manifested by transgenic mouse models.
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diabetic ketoacidosis at the age of four months. Management
was complicated by recurrent hypoglycaemia until death at
two years from severe diabetic ketoacidosis and infection.
Skeletal findings were consistent with spondyloepiphyseal
dysplasia and included bilateral femoral fractures.6 Direct
sequencing of EIF2AK3 revealed a homozygous deletion of
four nucleotides (1563delGAAA) at the site of a GAAA 4 base
pair (bp) direct repeat in exon 9. This generates an immediate
premature termination codon at amino acid 523 (fig 1). DNA
from both the parents and from the proband’s unaffected
sister was sequenced and heterozygous deletions confirmed
in all three individuals. No other alterations were observed in
the exons or immediately adjacent intronic regions in the
affected individual or in either parent.
Case 2
Clinical features of the second case up to the age of four and a
half years were described previously and included spondy-
loepiphyseal dysplasia and generalised osteoporosis.4 This
child, again the offspring of consanguineous Saudi parents,
was diagnosed at two months with diabetes requiring insulin
therapy, but subsequently died of renal failure. The clinical
course was marked by severe intellectual impairment and
frequent unpredictable hypoglycaemic episodes. A brother,
Table 1 Primers used to amplify the EIF2AK3 gene
Exon Forward primer Reverse primer
Product size
(bp)
Annealing
temperature ( C˚)
1 Gagaggcaggcgtcagtg cgcgcgtaaacaagttgc 403 58.9
2 Tgagcatgtgggataagtgc tgccctaaagggacacaaac 333 60
3 Tcaggatcaagactccagctc tgacaacctcaggggaaaat 448 59.7
4 Ggagttggtaatctaactgatgc ccaacagcaacattatctgaa 328 62.5
5 Gccctcttgtggcataaatc ctgggagaggaagaaccgta 449 58
6 Tacttggggctctcagcttg ggcactcctgaagtaggaagg 374 58
7 Ccctccctgtttttgttgaa gggcaaagacagtcaggatt 389 60
8 Ctgggccatttgtttaactt tgaaattgtctcccaagatg 384 55.6
9 Tagttaaagacgggcctatt caagagtagctttggtggag 396 56
10 Aagactggagggatagcagt agatcttaggtcatttcttctttg 371 58.1
11 Tgaactgattttcacattaccac aattggcagcacttagaacc 340 58
12 Gccttcagggttgtcttact cattgtaatcacacaagcaaa 384 56
13 Acagagggtgcagttcaggt cacaatggttgccaatatgc 357 58
13 Aaggtcaagggagagaacct acctctgctctcagatgctt 555 58
14 Catgcacacccactgtactt ctggaacactactgccagttt 348 56
15 Ctttgggattcaataatgct ccaatctgctggtattaagaa 288 57.5
16 Tgtggaatctgtgggatgtg tgctaaggaccgcttacgtt 356 56
17 Ttttgccagcactgatttta tttcaagtctgcaattttgg 367 58.2
Amplification of exon 1 required the addition of 5% dimethyl sulphoxide to the reaction mixture.
Figure 1 Identification of Wolcott-
Rallison syndrome mutations in
EIF2AK3. Case 1 (left panel): sequences
shown for normal DNA, heterozygous
parents, and case 1. Deletion of GAAA
within one allele of parental DNA and
both alleles of case 1 causes a
frameshift in exon 9 and premature
stop codon at amino acid 523. Case 2
(right panel): substitution at +1 position
of intron 14 (IVS14+1G.A; asterisk in
case 2) disrupts the donor splice site
(arrow above normal DNA). G and T
are present with 100% frequency at the
+1 and +2 positions, respectively.13
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now nine years old, also has insulin dependent diabetes.
Diagnosed two weeks after birth, his management is
complicated by frequent hypoglycaemia. Two additional
siblings are unaffected. No DNA was available from these
latter three siblings, or from either parent. Direct sequencing
of genomic DNA from the deceased child revealed no
EIF2AK3 coding sequence alterations. However, a homozy-
gous GRA substitution was observed at position +1 of intron
14 (IVS14+1G.A; fig 1). Neural network prediction
program analysis (http://www.fruitfly.org/seq_tools/spli-
ce.html) shows that this alteration, which was not present
in 100 normal chromosomes, abolishes the donor splice site
at the exon 14/intron 14 boundary. A G nucleotide is
invariant at the +1 position of donor splice sites13 and GRA
substitution at this position, identified here, is the common-
est mutation to account for splicing abnormalities. RNA from
this patient was not available for analysis. However, inclusion
of part or all of intron 14 in the mRNA as a result of loss of
this splice donor site would bring a stop codon into frame
after 75 nucleotides.
Both of these mutations in EIF2AK3 are novel. However, as
with one of the three previously described mutations,9 they
are both predicted to result in truncated proteins that lack the
critical kinase domain. In the other two published cases,
single base pair substitutions that affect the kinase domain
were described, in one case altering a highly conserved site9
and in the other resulting in impaired in vitro function.8
Expression of EIF2AK3 in human tissues
Targeted mutation of the mouse Eif2ak3 gene results in
animals that appear normal at birth but have progressive
postnatal b cell failure.11 12 However, in humans, EIF2AK3
was previously identified by immunohistochemistry only in
somatostatin positive d cells of the pancreatic islet.14 To try to
resolve this anomaly, we studied fixed sections of human
adult pancreas by immunohistochemistry with a polyclonal
antibody to EIF2AK3. In adult pancreas, we found that
EIF2AK3 was expressed extensively in the islet, with a
predominance in b cells (fig 2, panels A to C). Furthermore,
in keeping with the exocrine pancreatic insufficiency
reported in a human patient7 and in one of the knockout
mouse models,12 weaker EIF2AK3 staining was also apparent
within the acinar tissue (fig 2, panel D).
The normal birth weights of infants with Wolcott-Rallison
syndrome and the unremarkable pancreatic organogenesis in
Eif2ak32/2 mice11 12 might suggest a minimal role for
EIF2AK3 during pancreatic development in utero. However,
pancreatic hypoplasia/hypotrophy has characterised several
cases of Wolcott-Rallison syndrome, either at diagnosis by
ultrasound or at necropsy.7 8 15 Also, we find that EIF2AK3 is
widely expressed within the human fetal pancreas at eight
weeks postconception, at which stage the organ is composed
of epithelial progenitor cells before islet or exocrine differ-
entiation16 (fig 2E). Furthermore, in our first case (case 11 of
table 2), diabetes developed only four days after premature
birth at 28 weeks’ gestation. Taken together, these observa-
tions indicate that the human fetal pancreas may not be
normal in Wolcott-Rallison syndrome. Consistent with this
suggestion, mutation of the Eif2ak3 enzyme target (Ser51Ala
of Eif2a) resulted in a 50% diminution of pancreatic insulin
content between mouse embryonic days 16.5 and 18.5.17
EIF2AK3 is only one of four kinases known to phosphorylate
EIF2A. It is therefore feasible that the precise phenotype of
the Wolcott-Rallison syndrome could depend not only on the
severity of the EIF2AK3 mutation, but also on the co-
expression and activity of the other kinases. In both humans
and mice, there appears to be an absolute requirement for
EIF2AK3 in postnatal pancreatic b cells. In contrast, in the
murine liver, Eif2ak3 function appears dispensable.11 12 It is
therefore interesting to note the recurrent hypoglycaemic
episodes and hepatic dysfunction/enlargement that charac-
terises eight of the 15 described cases of Wolcott-Rallison
Figure 2 Bright field localisation of EIF2AK3 protein in human fetal and adult tissues. Panels A to C: sections of adult pancreatic islet, counterstained
with toluidine blue. Immunohistochemistry shows brown diaminobenzidine staining for EIF2AK3 and red alkaline phosphatase staining for insulin (A),
glucagon (B), and somatostatin (SS) (C). Note the overlapping red and brown staining in b cells (A) compared with the largely discrete profiles in (B)
and (C). (D) Section of adult pancreatic exocrine tissue. (E) Nests of fetal pancreatic epithelial cells within mesenchymal stroma at 8 wpc. (F) Section of
adult liver; *biliary ductule; v, hepatic venule. (G) Longitudinal section of fetal rib at 8.5 wpc. Black arrow indicates perichondrial layer; white arrow
points to central cartilaginous matrix. (H) Fetal bronchus at 8.5 wpc. Panels I to M: fetal kidney at 8.5 wpc. (I) Note paucity of staining in outer cortex
(double headed arrow). (J) to (M): Higher magnification views of (I) showing three examples of dense peritubular stromal staining, closely associated
with glomeruli (g) ((J) to (L)) and tubular staining (M). Note the similarity of intracellular staining between the fetal epithelial structures of (E), (H), and
(M). Size bar represents 150 mm ((A) to (E), (G), (H), (J) to (M)), 250 mm (F), and 750 mm (I). Wpc, weeks postconception.
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syndrome (ours4 6 and those of others3 5 8 15 (table 2)). These
clinical data are reminiscent of the fatal hypoglycaemia of the
Eif2ASer51Ala mutant mice.17 In combination, it appears
likely that in the human but not the mouse hepatic EIF2AK3
may have an important metabolic role that is not compen-
sated for by other enzymes capable of phosphorylating
EIF2A. Certainly, EIF2AK3 is strikingly expressed in the
perivenous regions of human adult liver (fig 2F), a major site
of endoplasmic reticulum associated glycogenolysis.18 19
However, it is intriguing that the fatal hypoglycaemia of
the Ser51Ala Eif2a mice was associated more with defective
gluconeogenesis,17 a pathway with greater capacity in
periportal hepatocytes. The reason for this discrepancy is
unclear.
Despite initially normal serum creatinine and renal
ultrasound, our second case (case 8 of table 2) subsequently
died during childhood of renal failure.4 Four other reports of
Wolcott-Rallison syndrome have included significant renal
impairment1 3 and necropsy findings of non-diabetes related
pathology.3 5 8 15 No renal abnormality has been described in
either Eif2ak3 knockout or Eif2Ser51Ala mouse models.11 12 17
However, we observe striking EIF2AK3 expression during
human fetal renal development. There is minimal expression
detected in the outermost nephrogenic cortex (fig 2, panel I),
but robust detection is observed in the renal capsule and
inner stromal tissue that surrounds tubules (fig 2, panels I to
L). EIF2AK3 is also expressed in the developing tubules (fig
2, panel M), with an intracellular distribution similar to
that observed in fetal pancreatic and bronchial epithelial
cells (fig 2, panels E and H). Finally, EIF2AK3 is detected
in the perichondrial layer and inner cartilaginous matrix
of the developing limbs and axial skeleton (fig 2,
panel G), consistent with the bony malformations that
form part of both the human and the murine mutation
phenotypes.12
Conclusions
We have described two novel mutations in EIF2AK3, both of
which reinforce the pathogenic significance of loss of the
kinase domain—a finding consistent across all five Wolcott-
Rallison syndrome mutations characterised to date.8 9 The
phenotypic features of these cases and of the knockout
mouse models are entirely concordant with the expression
profile of EIF2AK3 that we observe in human islets of
Langerhans and elsewhere in the pancreas, including the
lower levels of detection in exocrine tissue. These expression
patterns appear much more in keeping with the known
clinical features of Wolcott-Rallison syndrome than do pre-
vious results that indicated localisation of EIF2AK3 limited to
islet d cells.14 Furthermore, the likelihood of interspecies
differences in the phosphorylation of EIF2A is suggested by
the presence in Wolcott-Rallison syndrome of hypoglycaemic
complications, hepatic dysfunction, and renal complications
that are not observed in transgenic mice models.
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Table 2 Reported human cases of Wolcott-Rallison syndrome and transgenic mouse models
Human Mouse
Features 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Harding Zhang
* *
Eif2ak3
2/2
Eif2ak3
2/2
Scheuner
Eif2aSer51Ala
Age of onset of DM 6 w 8 w 6 w 4 w 3 w 5 w 10 w 8 w 2 w 12 w 4 d1 30 m ,6 m,6 m 8 w 2–4 w ,3 w Hypoglycaemia
Epiphyseal dysplasia + + + + + + + + + + + + + + +
Osteoporosis/fractures + No + No + No + No No + + No +
Hypoglycaemia + + + + + + + No No +
Liver dysfunction + + + + No No +
Hepatomegaly + + + + + No
Renal abnormalities + + + + + No
Birth weight (kg) 3.25 2.80 3.03 1.101 Normal Normal Normal
Clinical exocrine
pancreas deficiency
+ No + + No
Pancreatic hypoplasia/
hypotrophy
+ + + No No No
Cardiac abnormality/
murmur
+ + + + + No
Epilepsy (clinical/EEG) + + + + No No No
Death 2 y 6 w 11 y ,15 y 4 y 2 y 5 m If
untreated
If
untreated

Cases 1–3: cases 1, 2, and 3 (siblings) from Wolcott and Rallison, 1972.1
Cases 4 and 5: cases 1 and 2 from Goumy et al, 1980.2
Cases 6 and 7: cases 1 and 2 (siblings) from Sto¨ss et al, 1982.3
Cases 8 and 9: cases 1* and 2 (siblings) from al-Gazali et al, 1995.4
Case 10: Stewart et al, 1996;5 Thornton et al, 1997.15 Enlarged kidneys, abnormal shape with minor histological abnormalities.
Case 11:* Bonthron et al, 1998.6
Case 12: Castelnau et al, 2000.7
Cases 13 and 14: Dele´pine et al, 2000.9 Although a diagnosis of Wolcott-Rallison syndrome made in these cases, no clinical description was provided.
Case 15: Biason-Lauber et al, 2001.8
Where possible a positive phenotypic comment is made, otherwise a box is left blank. An asterisk indicates the cases sequenced in the present study.
1Premature birth at 28 weeks’ gestation.
The Eif2aSer51Ala mice die of hypoglycaemia in the newborn period, although pancreatic insulin content is significantly reduced.
Death from hyperglycaemia if untreated.
d, day; DM, diabetes mellitus; m, month; w, week; y, year.
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